STOK at a glance
Stoke Therapeutics, Inc. (STOK, SEC CIK 1623526) filed its latest 10-K annual report on March 16, 2026, a 10-Q quarterly report on November 3, 2026, an 8-K current report on October 29, 2026 and Form 4 insider filings as recently as November 4, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Stoke Therapeutics, Inc. (STOK) reported revenue of $184.4 million (up 404.5% from FY2024) and a net loss of $6.9 million. Diluted EPS was -$0.12.
- As of September 30, 2026, 27 institutional investment managers tracked by SignalX reported holding Stoke Therapeutics, Inc. (STOK) shares worth $590.3 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Ticho Barry on November 2, 2026 of 200 shares at $26.99 per share.
- In the last 90 days, STOK insiders reported 0 open-market purchases ($0) and 6 open-market sales ($404K) on Form 4, a net sale of $404K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $184.4M
- +404.5% vs prior year
- Insiders · 90 days
- 0 buys · 6 sells
- Net −$404K
- 13F holders
- 27 funds
- $590.3M · +0 vs prior quarter
- Latest 8-K
- Oct 29, 2026
- Item 2.02
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business model: RNA-based medicines using proprietary TANGO platform to upregulate protein expression for treating severe genetic diseases
- New focus: Phase 3 study of zorevunersen for Dravet syndrome initiated May 2025, plus Phase 1 study of STK-002 for autosomal dominant optic atrophy
- Strategic shift: Emphasis on rapid commercial preparation in US, Canada, Mexico for zorevunersen; global commercial partner Biogen for other territories
- Notable metric: EMPEROR Phase 3 enrollment target ~150 patients; OLE studies sustained seizure reduction through 3 years in 74 patients enrolled
- Unique fact: Zorevunersen granted FDA Breakthrough Therapy Designation Dec 2024; Phase 1/2a and OLE data published in New England Journal of Medicine March 2026
Risk Factors
- Regulatory risk from FDA clinical holds: partial hold on zorevunersen doses removed, future holds possible delaying development
- Macroeconomic exposure: potential impacts from inflation, fluctuating interest rates, tariffs, recessions, and government shutdowns on operations
- Supply chain risk: dependency on third-party CMOs for clinical and commercial manufacturing supply and backup sources
- Competitive risk: uncertainty if regulatory labeling excludes secondary endpoints potentially weakening competitive positioning
- Financial risk: history of losses with anticipated continued deficits and need for additional funding before profitability achievable
Management Discussion & Analysis
- Revenue $184.4M in 2025 vs $36.6M in 2024, up $147.8M mainly from Biogen collaboration ($168.3M in 2025) offset by Acadia decline
- Net loss $6.9M in 2025 vs $89.0M in 2024; operating loss improved to $20.6M from $101.4M; operating margin approx. -11.2% vs -277.1%
- Best segment: Biogen collaboration revenue $168.3M in 2025, no revenue in 2024; worst: ADOA R&D costs mostly flat ($5.1M vs $5.8M) with limited impact on revenue
- Cash $390.9M at end 2025 vs $246.7M end 2024; capital raised via equity offerings netting $168.8M in 2025; no dividends or buybacks disclosed; expected to fund operations into 2028
- Forward outlook: expect increased R&D and SG&A costs to support clinical development and commercialization; risks from clinical, regulatory, and financing uncertainties remain
AI summary of the STOK 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Quarterly revenue $11.3M, up $0.7M YoY from $10.6M, driven by Acadia and Biogen collaborations
- Operating margin (77,315 ÷ 11,255) not disclosed as a percentage, versus (43,091 ÷ 10,632) not disclosed
- Best-performing program: zorevunersen R&D $28.7M vs $19.0M; ADOA $3.6M vs $1.6M
- Cash, equivalents and marketable securities $358.8M vs $390.9M at December 31, 2025; operations funded into early 2028
- Operating cash flow $(179.9)M vs $76.0M; financing provided $156.4M, including $146.4M from equity offering
Risk Factors
- Newly added regulatory risk: FDA staffing reductions and funding constraints could delay reviews, guidance and approvals under the current administration
- Most materially updated pricing risk: finalized 2026 GLOBE Model begins January 1, 2027, potentially reducing Medicare Part B drug prices
- Clinical risk: STK-002 entered its OSPREY Phase 1 study after first-patient dosing in February 2026
- Near-term operational risk: EMPEROR Phase 3 execution depends on hospital staffing and patient enrollment, despite first dosing in August 2025
- Liquidity risk: $358.8 million cash, equivalents and marketable securities expected to fund operations into early 2028
AI summary of the STOK 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q3 2026 financial results announced for the quarter ended September 30, 2026
- Investors should review the accompanying press release for reported financial figures and operating updates
Item EX-99.1: Item EX-99.1
- Phase 3 EMPEROR enrollment complete at 162 patients, with data readout anticipated Q3 2027 and U.S. NDA planned H2 2027
- Approximately 110 patients reached Week 28, the primary seizure endpoint, while no patients have discontinued treatment
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Edward M. Kaye resigning as Class III director and R&D Committee member effective September 23, 2026
- Board appointed Alexander (Bo) Cumbo as independent Class III director through the 2028 Annual Meeting
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 financial results announced for quarter ended June 30, 2026
- Investors should review the accompanying press release for reported figures and management commentary
Item EX-99.1: Item EX-99.1
- Phase 3 EMPEROR enrollment complete at 162 patients, with primary data readout expected Q3 2027 and rolling U.S. NDA completion targeted H2 2027
- FDA pre-NDA meeting planned H2 2026, with rolling U.S. NDA submission targeted Q1 2027
AI summaries of STOK 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for STOK
Don't miss the next STOK filing
- Alerts as it files. A push when STOK files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut STOK, by share count.
- Ask anything. An AI agent that reads every STOK filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Ticho Barry | Sell | Nov 2, 2026 | 200 | $26.99 |
| Ticho Barry | Sell | Nov 2, 2026 | 6,995 | $26.38 |
| Allan Jonathan | Sell | Oct 2, 2026 | 627 | $26.33 |
| Ticho Barry | Sell | Oct 1, 2026 | 1,051 | $26.16 |
| Cumbo Alexander | A | Sep 23, 2026 | 39,674 | - |
| Ticho Barry | Sell | Sep 1, 2026 | 1,600 | $31.06 |
| Ticho Barry | Sell | Sep 1, 2026 | 3,945 | $30.51 |
| Allan Jonathan | Sell | Aug 18, 2026 | 145 | $32.47 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | $8.8M | $36.6M | $184.4M |
| Operating Income | - | -$101.4M | -$20.6M |
| Net Income | -$104.7M | -$89.0M | -$6.9M |
| Op. Margin | - | -277.3% | -11.2% |
| Net Margin | -1192.5% | -243.4% | -3.7% |
| Balance Sheet | |||
| Total Assets | - | $271.6M | $418.4M |
| Equity | $159.6M | $229.0M | $352.5M |
| ROE | -65.6% | -38.9% | -2.0% |
| Per Share | |||
| EPS | - | $-1.65 | $-0.12 |
| Cash Flow | |||
| Operating CF | -$81.1M | -$86.9M | $45.6M |
| CapEx | - | $203K | $670K |
Source: XBRL data in Stoke Therapeutics, Inc. (STOK)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate STOK share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 27 | $590.3M |
| Q2 2026 | 27 | $897.0M |
| Q1 2026 | 27 | $832.1M |
| Q4 2025 | 22 | $759.6M |
| Q3 2025 | 24 | $572.3M |
| Q2 2025 | 23 | $282.0M |
| Q1 2025 | 20 | $94.8M |
| Q4 2024 | 19 | $65.8M |
- BlackRock+470.5K (+8%)
- Goldman Sachs Group+434.2K (+75%)
- Millennium Management+254.8K (+98%)
- Vanguard Capital Management LLC+146.5K (+6%)
- Two Sigma Investments+146.1K (+234%)
- Morgan Stanley−242.5K (-7%)
- State Street Corp−235.1K (-8%)
- T. Rowe Price Group−233.6K (-9%)
- Dimensional Fund Advisors−89.6K (-9%)
- Principal Financial Group−61.3K (-88%)
- FMR LLC (Fidelity)−5.31M
Source: 13F-HR filings on SEC EDGAR (aggregated from 189 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
STOK filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 4, 2026 | - | - | - |
| 10-Q | Nov 3, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Oct 29, 2026 | - | Analysis | - |
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Oct 2, 2026 | - | - | - |
| 8-K | Sep 25, 2026 | - | Analysis | - |
| 4 | Sep 25, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| 4 | Aug 5, 2026 | - | - | - |
| 8-K | Aug 3, 2026 | - | Analysis | - |
| 10-Q | Aug 3, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 3, 2026 | - | Analysis | - |
| 4 | Jul 17, 2026 | - | - | - |
| 4 | Jul 17, 2026 | - | - | - |
| 4 | Jul 6, 2026 | - | - | - |
| 8-K | Jun 30, 2026 | - | Analysis | - |
| 4 | Jun 18, 2026 | - | - | - |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
STOK SEC filings: frequently asked questions
Are STOK insiders buying or selling?
In the last 90 days, Stoke Therapeutics, Inc. (STOK) officers, directors and 10% owners reported no open-market purchases and 6 open-market sales worth $403,975 by 2 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold STOK stock?
As of September 30, 2026, the largest Stoke Therapeutics, Inc. (STOK) holders among the 13F filers tracked by SignalX were BlackRock ($165.0 million), Morgan Stanley ($83.5 million), Vanguard Capital Management LLC ($71.1 million), State Street Corp ($68.0 million), T. Rowe Price Group ($63.1 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was STOK's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Stoke Therapeutics, Inc. (STOK) reported revenue of $184.4 million (up 404.5% from FY2024) and a net loss of $6.9 million. Diluted EPS was -$0.12. The figures come from the XBRL data in the 10-K.
What are the main risks in STOK's latest 10-K?
In the 10-K filed March 16, 2026, Stoke Therapeutics, Inc. (STOK) flagged: Regulatory risk from FDA clinical holds: partial hold on zorevunersen doses removed, future holds possible delaying development. Macroeconomic exposure: potential impacts from inflation, fluctuating interest rates, tariffs, recessions, and government shutdowns on operations. (AI summary of the Risk Factors section.)
What did STOK report in its latest 8-K?
Stoke Therapeutics, Inc. (STOK) filed an 8-K on October 29, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 financial results announced for the quarter ended September 30, 2026.
What are the latest STOK SEC filings?
Stoke Therapeutics, Inc. (STOK) filed its latest 10-K annual report on March 16, 2026, a 10-Q quarterly report on November 3, 2026, an 8-K current report on October 29, 2026 and a Form 4 insider filing on November 4, 2026.
What is STOK's SEC CIK number?
Stoke Therapeutics, Inc. (STOK)'s SEC Central Index Key (CIK) is 1623526. EDGAR lists every STOK filing under that number.
Ask anything about STOK
The research agent reads STOK's filings, financials, insider trades and 13F holders, then answers with sources.